University of Dundee

School of Medicine, Division of Molecular & Clinical Medicine

 

Graham Rena

METFORMIN: USEFUL IN NON-DIABETIC CARDIOVASCULAR DISEASE?
A major recent focus has been metformin, which is the gold-standard treatment of insulin resistance in type 2 diabetes. The target of this drug has been unknown since the drug’s antihyperglycaemic properties were identified almost a century ago. Our work has included high-profile investigation of anti-inflammatory effects of the drug, which may contribute towards cardioprotective effects in patients and which we have found occurring irrespective of diabetes status (Cameron and co-workers (Circ. Res. 2016).

Expertise

  • Cell signalling
  • Metabolic studies
  • Gene expression
  • Validation in clinical samples

Interested in collaborating on

  • Inflammation in CVD

Website
g.rena@dundee.ac.uk

Ninewells Hospital and Medical School
Dundee DD1 9SY
Scotland, United Kingdom